Biopharmaceutical company specializing in development of serotonergic therapies to treat mental health conditions Bright Minds Biosciences Inc. (CSE: DRUG) has officially secured an approval to get its stock listed on the NASDAQ Capital Market.
The approval was granted by The NASDAQ Stock Market LLC and the company’s common shares will start trading on NASDAQ from November 8 under the ticker symbol ‘DRUG’.
Nonetheless, the company will also retain its listing on the on the Canadian Securities Exchange (CSE) under the same ticker symbol.
The company’s co-founder and chief executive officer, Ian McDonald, acknowledges the NASDAQ listing as one which will give the company new synergies in terms of diverse capital base and advancement of innovative drug candidates.
“Our listing on Nasdaq marks an important corporate milestone for Bright Minds, as we continue to advance our innovative drug candidates in pursuit of an improved generation of targeted serotonin-based therapies. With encouraging preclinical data across several indications, we are progressing toward first-in-human trials with our lead drug candidate, BMB-101, for the treatment of Dravet syndrome, a devastating congenital and genetic disease affecting the nervous system. We expect to commence the trials in the first half of 2022,” said the CEO.
